ArticleAging2019
Narrative impairment, white matter damage and CSF biomarkers in the Alzheimer's disease spectrum.
Article in Aging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Temporal-Targeted Accelerated 40 Hz tACS Enhances Cognitive Function and Network Integration in Alzheimer's Disease: A Randomized Clinical Trial.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Performance of plasma biomarkers for diagnosis and prediction of dementia in a Brazilian cohort.Nature communications · 2025Article
- White matter tract correlations with spoken language in cerebrovascular disease.Brain communications · 2025Article
- Cortical folding correlates to aging and Alzheimer's Disease's cognitive and CSF biomarkers.Scientific reports · 2024Article
- The Discourse Profile in Corticobasal Syndrome: A Comprehensive Clinical and Biomarker Approach.Brain sciences · 2022Article
- Age-linked suppression of lipoxin A4 associates with cognitive deficits in mice and humans.Translational psychiatry · 2022Article
- Plasma phosphorylated-tau181 levels reflect white matter microstructural changes across Alzheimer's disease progression.Metabolic brain disease · 2022Article
- Can discourse processing performance serve as an early marker of Alzheimer's disease and mild cognitive impairment? A systematic review of text comprehension.European journal of ageing · 2022Review
- Neuroimaging Research on Dementia in Brazil in the Last Decade: Scientometric Analysis, Challenges, and Peculiarities.Frontiers in neurology · 2021Review
- Cerebrospinal fluid irisin correlates with amyloid-β, BDNF, and cognition in Alzheimer's disease.Alzheimer's & dementia (Amsterdam, Netherlands) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNarrative discourse (ND) refers to one's ability to verbally reproduce a sequence of temporally and logically-linked events. Impairments in ND may occur in subjects with Amnestic Mild Cognitive Impairment (aMCI) and Alzheimer's Disease (AD), but correlates across this function, neuroimaging and cerebrospinal fluid (CSF) AD biomarkers remain understudied.
objectivesWe sought to measure correlates among ND, Diffusion Tensor Imaging (DTI) indexes and AD CSF biomarkers in patients within the AD spectrum.
resultsGroups differed in narrative production (NProd) and comprehension. aMCI and AD presented poorer inference abilities than controls. AD subjects were more impaired than controls and aMCI regarding WB (p<0.01). ROIs DTI assessment distinguished the three groups. Mean Diffusivity (MD) in the uncinate, bilateral parahippocampal cingulate and left inferior occipitofrontal fasciculi negatively correlated with NProd. Changes in specific tracts correlated with T-tau/Aβ1-42 ratio in CSF.
conclusionsAD and aMCI patients presented more ND impairments than controls. Those findings were associated with changes in ventral language-associated and in the inferior parahippocampal pathways. The latest were correlated with biomarkers' levels in the CSF.
methodsAD (N=14), aMCI (N=31) and Control (N=39) groups were compared for whole brain (WB) and regions of interest (ROI) DTI parameters, ND and AD CSF biomarkers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.